Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01772732

Recruitment Status : Unknown

Verified April 2015 by Jiangsu Simcere Pharmaceutical Co., Ltd..
Recruitment status was: Recruiting

First Posted : January 21, 2013

Last Update Posted : April 9, 2015

Sponsor:

Information provided by (Responsible Party):

Jiangsu Simcere Pharmaceutical Co., Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	December 2015
Estimated Study Completion Date :	December 2015

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hu XS, Han XH, Yang S, Li N, Wang L, Song YY, Mu H, Shi YK. Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial. Cancer Manag Res. 2019 May 13;11:4449-4459. doi: 10.2147/CMAR.S189626. eCollection 2019.

To Top